aTyr Pharma, Inc. Cash Flow-to-Debt Ratio
aTyr Pharma, Inc. cash flow-to-debt ratio. aTyr Pharma, Inc. (ATYR) has a Cash Flow-to-Debt Ratio of -0.45x as of December 2025, meaning its operating cash flow of $-12.20 Million could theoretically repay 0% of its total liabilities ($26.88 Million) in one year. Check cash flow quality index of aTyr Pharma, Inc. to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of aTyr Pharma, Inc. (2012–2025)
Cash flow-to-debt ratio of aTyr Pharma, Inc. from 2012 to 2025. Historical debt coverage capacity for aTyr Pharma, Inc. across 14 annual periods. Check aTyr Pharma, Inc. (ATYR) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
aTyr Pharma, Inc. Cash Flow-to-Debt Ratio by Year (2012–2025)
aTyr Pharma, Inc. cash flow-to-debt ratio by year from 2012 to 2025. Year-by-year debt coverage analysis for aTyr Pharma, Inc.. For the full cash flow conversion analysis, see aTyr Pharma, Inc. operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.31x | $-61.99 Million | $26.88 Million | ▲ +9.9% |
| 2024 | -2.56x | $-69.12 Million | $27.00 Million | ▼ -132.6% |
| 2023 | -1.10x | $-33.22 Million | $30.18 Million | ▲ +35.6% |
| 2022 | -1.71x | $-41.89 Million | $24.50 Million | ▲ +66.9% |
| 2021 | -5.16x | $-33.08 Million | $6.41 Million | ▼ -144.2% |
| 2020 | -2.11x | $-15.30 Million | $7.24 Million | ▼ -60.1% |
| 2019 | -1.32x | $-20.01 Million | $15.16 Million | ▲ +18.9% |
| 2018 | -1.63x | $-31.06 Million | $19.10 Million | ▲ +3.6% |
| 2017 | -1.69x | $-42.36 Million | $25.11 Million | ▲ +43.4% |
| 2016 | -2.98x | $-52.86 Million | $17.72 Million | ▼ -18.5% |
| 2015 | -2.52x | $-36.80 Million | $14.62 Million | ▼ -1130.8% |
| 2014 | -0.20x | $-22.82 Million | $111.65 Million | ▼ -25.0% |
| 2013 | -0.16x | $-17.31 Million | $105.87 Million | ▲ +87.5% |
| 2012 | -1.30x | $-11.38 Million | $8.73 Million | — |